Background {#s1}
==========

Renal cell cancer (RCC) is the third most fatal genitourinary malignancy, accounting for 2--3% of all adult malignancies in humans ([@B1]). With the widespread use of cross-sectional imaging in the last decades, more renal tumors are expected to be detected as local lesions. Although the conventional treatment for RCC is radical nephrectomy (RN), patients with RN have substantial risk of progression to future renal insufficiency ([@B2]). Hence, nephron-sparing surgery (NSS), involving preservation of normal kidney parenchyma, has become widely accepted as the standard treatment of small renal masses ([@B3]).

Traditionally, nephron-sparing surgery includes partial nephrectomy and simple enucleation. Current evidence demonstrates that NSS leads to equal oncological outcomes compared to RN for pathologically staged T1- T2 tumors ([@B4], [@B5]). However, 20--40% of patients experience local recurrence or distant metastasis after NSS ([@B6], [@B7]). This has led to attempts to identify clinicopathological factors to assist clinical decision-making and patient counseling. Nowadays, some prognostic parameters, such as TNM staging system ([@B8]), tumor size ([@B9]), histological subtype ([@B10]) and Fuhrman grade ([@B11])have been developed to predict disease recurrence or survival outcomes. However, the prognostic value of these parameters are controversial according to published studies, and there is no consensus about which patients are at greater risk to develop recurrence or distant metastasis.

These controversies could be a result of differences in limited sample sizes and (or) individual variations. To date, there is no comprehensive study containing the clinicopathological variables for RCC. In this setting, we searched the relevant studies and conducted this meta-analysis in order to assess the potential prognostic factors for oncologic outcomes of recurrence, recurrence-free survival (RFS) and overall mortality (OM) after NSS in RCC patients.

Materials and Methods {#s2}
=====================

Search Strategy
---------------

Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) protocols ([@B12]), relevant studies were searched through the electronic databases of PubMed, EMBAS, and Web of Science up to March, 2019.The following MeSH terms and text words were used in combination: "renal cell cancer," "nephron-sparing surgery," "partial nephrectomy," "simple enucleation," "prognosis," "clinicopathological," and "survival." We also searched relevant studies and reviews by manually screening the references list. The search was restricted to studies of human subjects written in English. Institutional Review Board approval was not required for this study.

Inclusion and Exclusion Criteria
--------------------------------

The criteria for inclusion were listed as follows: (1) patients with a diagnosis of RCC was pathologically confirmed; (2) the study considered NSS as a primary treatment; (3) the study included clinicopathological factors for oncological outcomes in RCC; and (4) the authors offered the hazard ratios (HRs) and their 95% confidence intervals (CIs) in the paper. The exclusion criteria for the primary studies included following criteria: (1) duplicate publications; (2) studies which did not provide sufficient data to acquire HRs and 95%CIs; (3) non-original articles (e.g., reviews, letters, case reports, and author\'s reply). When multiple articles were published about the same population, the article reporting the most complete data would be used.

Data Extraction and Quality Assessment
--------------------------------------

Two authors (ZlZ and HZ) independently extracted data from each included paper. Any disagreement was resolved by discussing with the senior author (BW). The following extracted information was collected and recorded in standardized form: first author, year of publication, ethnicity, number of patients, recruitment period, age, sex, type of NSS, histopathological information, follow-up time, and HRs for survival outcome (recurrence, RFS, and OM) with its 95% CIs. If one study reported results using both multivariate and univariate analysis, we choose the results from multivariate analysis, as it accounts for confounding factors and is more precise.

The Newcastle--Ottawa Quality Assessment Scale (NOS) ([@B13]) was applied to assess the methodological quality of each included study. Selection of cohorts, comparability, and ascertainment of outcomes were involved in this assessment scale. Only studies with an NOS score \>6 were defined as high quality and finally included.

Statistical Analysis
--------------------

The software Stata version 12.0 (STATA Corporation, College Station, TX) was used to perform the meta-analysis of the included articles. HRs with their 95% CIs extracted from each publication were applied to calculate pooled HRs. Pooled HRs were used to identify the correlation between clinicopathological risk factors and patient survival. A pooled HR \>1 indicated a poorer survival for the patients with a certain clinicopathological feature. The *Chi*^2^ and *I*^2^ statistic were performed to evaluate inter-study heterogeneity. The value of *P*~heterogeneity~ \> 0.1 and I^2^ \< 50% represents low-level heterogeneity. If *P*~heterogeneity~ \> 0.1 and *I*^2^ \< 50%, a fixed-effects model was applied; otherwise, a random-effects model was applied.

Subgroup and meta-regression analysis based on geographical region, publication year, sample size, and follow-up duration were performed for recurrence analysis to identify the source of heterogeneity. Funnel plots and Begg\'s test were applied to assess potential publication bias. Sensitivity analysis was also conducted by deleting one single study to measure the reliability of the pooled results. Two-sided value of *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Search Results
--------------

The process of searching articles is presented as a flow diagram in [Figure 1](#F1){ref-type="fig"}. A total of 3,653 potentially relevant studies were identified through the primary study searching. Of all identified records, 1,947 were excluded due to duplicate studies. After title and/or abstracts scanning, 559 articles remained for full-text assessment. Then 543 articles were further excluded by the inclusion criteria. Ultimately, 17 published retrospective studies that met our inclusion criteria were included in this meta-analysis ([@B14]--[@B30]), containing a total of 38,522 patients (ranging from 69 to 20,762).

![Flow chart of the studies selection process in the meta-analysis.](fonc-10-00286-g0001){#F1}

Characteristics of the Studies
------------------------------

The main clinicopathological characteristic of included studies are presented in [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}. Totally, all the studies were written in English and published from 2002 to 2018. The median follow-up intervals were from 19 to 102 months. In these studies, nine studies were reported from American countries (USA, Canada, Mexico, Argentina), four from Asian countries (Korea, Japan, Indian), three from European countries (Italy, France), and one being a multi-center study. Thirteen studies reported the correlation between recurrence and clinicopathological features; the remaining three studies reported RFS and/or OM and clinicopathological details. The results of the NOS assessment are summarized in [Supplementary Table S1](#SM4){ref-type="supplementary-material"}; the quality scores of the studies varied from 6 to 8, with a mean of 7.5.

###### 

The main characteristics of the eligible studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**                     **Country**    **Recruitment period**   **No. of patients**   **Age (years)**   **Gender (m/f)**   **Follow-up (months)**   **Surgical operation (open vs. minimally invasive)**
  ---------------------------------- -------------- ------------------------ --------------------- ----------------- ------------------ ------------------------ ------------------------------------------------------
  Wood et al. ([@B14])               USA            2000--2014               207                   NA                111/86             Median (range)\          PN(179 vs. 28)
                                                                                                                                        23 (2--107)              

  Tellini et al. ([@B15])            Italy          1983--2014               459                   Mean ± SD\        328/131            Median (IQR)\            NSS
                                                                                                   60.7 ± 12.7                          96 (74--131)             

  Shum et al. ([@B16])               Indian         2004--2009               20,762                NA                12,745/8,017       Median\                  PN
                                                                                                                                        70.3                     

  Marchinena et al. ([@B17])         Argentina      2010--2015               314                   Mean ± SD\        218/96             Median (IQR)\            NSS(142 vs. 172)
                                                                                                   58.3 ± 12                            24 (12--40)              

  Yoo et al. ([@B18])                Korea          1998--2012               843                   Mean ± SD\        636/207            Median\                  PN(468 vs. 375)
                                                                                                   53.3 ± 11.7                          67                       

  Bansal et al. ([@B19])             Canada         2011--2014               1,103                 Median (range)\   654/389            Median (IQR)\            PN(599 vs. 504)
                                                                                                   61 (53--70)                          19 (5--42)               

  Shah et al. ([@B20])               Muti-centers   2006--2013               1,240                 Mean ± SD\        832/408            Median (IQR)\            PN
                                                                                                   59.1 ± 11.9                          33 (15--57)              

  Nguyen et al. ([@B21])             USA            2006--2014               1,668                 Median (IQR)\     1,131/555          Median (IQR)\            PN
                                                                                                   60 (51--68)                          33.6 (13.2--60)          

  Maurice et al. ([@B22])            USA            2003--2006               6,038                 Median (IQR)\     3,644/2,394        Median (IQR)\            PN
                                                                                                   58 (49--67)                          71 (56--85)              

  Lee et al. ([@B23])                Korea          1997--2014               1,367                 NA                1,016/351          Median (IQR)\            PN
                                                                                                                                        54 (29--81)              

  Zargar-Shoshtari et al. ([@B24])   Mexico         1999--2012               505                   Median (range)\   314/191            Median (IQR)\            NSS(377 vs. 128)
                                                                                                   61 (22--88)                          38.3 (6--88)             

  Minervini et al. ([@B25])          Italy          2005--2011               304                   Mean ± SD\        192/112            Median (range)\          SE
                                                                                                   63 ± 13                              52 (12--96)              

  Bigot et al. ([@B26])              France         1998--2012               168                   Median (range)\   102/66             Mean (range)\            NSS(153 vs.)
                                                                                                   59 (20--85)                          30 (1--254)              

  Lane et al. ([@B27])               USA            1999--2008               1,616                 Median (IQR)\     1,021/595          Median (IQR)\            PN(626 vs. 395)
                                                                                                   61 (52--70)                          58.8 (39.6--81.6)        

  Yossepowitch et al. ([@B28])       USA            1972--2005               1,390                 Median (IQR)\     954/436            Median (IQR)\            PN
                                                                                                   61 (52--69)                          40.8 (16.8--70.8)        

  Senga et al. ([@B29])              Japan          1990--1999               469                   NA                361/108            Mean (range)\            PN
                                                                                                                                        48.2 (1--158)            

  Castilia et al. ([@B30])           USA            1976--1988               69                    Mean (range)\     47/22              Median\                  NSS
                                                                                                   61 (36--85)                          102                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*m/f, male/female; SD, standard deviation; IQR, inter quartile range; NA, data not applicable; PN, partial nephrectomy; SE, simple enucleation; NSS, nephron-sparing surgery*.

###### 

The main pathologic features of the eligible studies.

  **Study**                          **Staging system**   **Grading system**   **PSM / NSM**   **Stage1-2/ 3-4**   **Grade 1-2/ 3-4**   **Tumor size (cm)**
  ---------------------------------- -------------------- -------------------- --------------- ------------------- -------------------- ----------------------------
  Wood et al. ([@B14])               2010 AJCC            Furman               12/195          193/14              125/82               NA
  Tellini et al. ([@B15])            2010 AJCC            Furman               27/432          441/18              NA                   Mean ± SD3.1 ± 1.3
  Shum et al. ([@B16])               2010 AJCC            Furman               1,278/19,484    NA                  14,495/3,887         NA
  Marchinena et al. ([@B17])         2002 AJCC            Furman               22/292          314/10              258/7                Median (IQR)2.9 (2.1--3.8)
  Yoo et al. ([@B18])                NA                   Furman               NA              843/0               583/260              Mean ± SD2.2 ± 0.8
  Bansal et al. ([@B19])             NA                   Furman               71/972          1,036/67            829/274              Median3.0
  Shah et al. ([@B20])               2002 AJCC            Furman               97/1,143        1,240/0             927/313              Mean ± SD3.2 ± 1.7
  Nguyen et al. ([@B21])             2009 AJCC            NA                   NA              1,450/218           NA                   Median (IQR)3.0 (2.0--4.0)
  Maurice et al. ([@B22])            2010 AJCC            Furman               302/6,038       5,898/140           5,133/905            Median (IQR)2.5 (1.9--3.5)
  Lee et al. ([@B23])                2009 AJCC            Furman               10/1,357        1,324/43            927/440              NA
  Zargar-Shoshtari et al. ([@B24])   2009 AJCC            Furman               3/502           488/17              258/247              Median (range)3 (0.2--13)
  Minervini et al. ([@B25])          2009 AJCC            Furman               NA              279/25              276/28               Mean (range)3.4 (1--12.5)
  Bigot et al. ([@B26])              2009 AJCC            Fuhrman              14/154          107/19              63/163               Median (range)8 (7--18)
  Lane et al. ([@B27])               NA                   Furman               7/1609          NA                  1,200/416            Median (IQR)3.0 (2.2-4.0)
  Yossepowitch et al. ([@B28])       NA                   NA                   77/1,313        1,311/79            NA                   Median (IQR)3.0 (2.2-4.3)
  Senga et al. ([@B29])              1997 AJCC            Furman               NA              NA                  462/7                NA
  Castilia et al. ([@B30])           1997 AJCC            Furman               NA              46/23               61/8                 Median (range)4.4 (1-11.3)

*SD, standard deviation; IQR, inter quartile range; NA, data not applicable*.

Survival Outcome
----------------

Fourteen studies with 10,106 patients was enrolled to disclose the clinicopathological factors in patients with NSS.As shown in [Figure 2](#F2){ref-type="fig"}, positive surgical margin(PSM) (pooled HR = 1.47; 95% CI:1.24--1.73; *P* \< 0.001, [Figure 2A](#F2){ref-type="fig"}), higher Fuhrman grade (pooled HR = 1.58, 95% CI:1.10--2.28, *P* = 0.013, [Figure 2B](#F2){ref-type="fig"}), higher pathological stage (pooled HR = 1.72; 95% CI:1.40--2.12; *P* \< 0.001, [Figure 2C](#F2){ref-type="fig"}) and large tumor size (pooled HR = 1.09; 95% CI:1.03--1.16; *P* = 0.003, [Figure 2D](#F2){ref-type="fig"}) were significantly associated with higher recurrence risk. However, age (pooled HR = 1.00; 95% CI: 1.00--1.01; *P* = 0.257, [Figure 3A](#F3){ref-type="fig"}), sex (male vs. female) (pooled HR = 1.04, 95% CI: 0.89--1.21, *P* = 0.605, [Figure 3B](#F3){ref-type="fig"}) and surgical approach (laparoscope vs. open) (pooled HR = 0.80, 95% CI: 0.59--1.07, *P* = 0.129, [Figure 3C](#F3){ref-type="fig"}) had no effect on recurrence.

![Forest plot of hazard ratio for the association between clinicopathological features and recurrence risk in RCC patients following NSS: **(A)** positive surgical margin; **(B)** higher Fuhrman grade; **(C)** higher pathological stage; **(D)** large tumor size.](fonc-10-00286-g0002){#F2}

![Forest plot depiction of the association between clinicopathological factors and recurrence risk in RCC patients following NSS: **(A)** age; **(B)** sex; **(C)** surgical approach.](fonc-10-00286-g0003){#F3}

We also investigated the potential clinicopathological risk factors for RFS and OM in three studies with 28,416 patients. As shown in [Table 3](#T3){ref-type="table"}, PSM (pooled HR = 1.87,95% CI:1.32--2.66, *P* \< 0.001, [Supplementary Figure S1a](#SM1){ref-type="supplementary-material"}), higher Fuhrman grade (pooled HR = 1.75, 95% CI:1.30--2.37, *P* \< 0.001, [Supplementary Figure S1b](#SM1){ref-type="supplementary-material"}), higher pathological stage (pooled HR = 2.21, 95% CI:1.64--2.97, *P* \< 0.001, [Supplementary Figure S1c](#SM1){ref-type="supplementary-material"}) and large tumor size (pooled HR = 1.18, 95% CI:1.06--1.30, *P* = 0.002, [Supplementary Figure S1d](#SM1){ref-type="supplementary-material"}) were significantly associated with poor RFS. However, age (pooled HR = 1.01, 95% CI: 0.98--1.04, *P* = 0.488, [Supplementary Figure S1e](#SM1){ref-type="supplementary-material"}) and sex (male vs. female) (pooled HR = 1.04, 95% CI: 0.90--1.21, *P* = 0.592, [Supplementary Figure S1f](#SM1){ref-type="supplementary-material"}) had no relationship with RFS. Also, PSM (pooled HR = 1.15, 95% CI: 1.07--1.23, *P* \< 0.001, [Supplementary Figure S2a](#SM2){ref-type="supplementary-material"}) and large tumor size (pooled HR = 1.01, 95% CI: 1.00--1.02, *P* = 0.004, [Supplementary Figure S2b](#SM2){ref-type="supplementary-material"}) indicated a strong association with OM. Meanwhile, OM has no association with sex (male vs. female) (pooled HR = 1.08, 95% CI: 0.96--1.23, *P* = 0.193, [Supplementary Figure S2c](#SM2){ref-type="supplementary-material"}). Taken together, the results demonstrated that worse pathological features may be considered as significant biomarkers for prognosis of patients following NSS.

###### 

The pooled HR and 95% CIs for the prognostic factors in RFS and OM.

  **Analysis specification**   **No. of studies**   **Study heterogeneity**   **Effects model**   **Pooled HR(95% CI)**   ***P*-Value**      
  ---------------------------- -------------------- ------------------------- ------------------- ----------------------- ------------------ ---------
  **RFS**                                                                                                                                    
     Age                       2                    79.3                      0.028               Random                  1.01(0.98, 1.04)   0.488
     Tumor size                3                    61                        0.077               Random                  1.18(1.06, 1.30)   0.002
     Sex (male vs. female)     2                    0                         0.587               Fixed                   1.04(0.90, 1.21)   0.592
     Fuhrman grade             3                    0                         0.524               Fixed                   1.75(1.30, 2.37)   \<0.001
     Pathological stage        3                    0                         0.423               Fixed                   2.21(1.64, 2.97)   \<0.001
     PSM                       2                    0                         0.355               Fixed                   1.87(1.32, 2.66)   \<0.001
  **OM**                                                                                                                                     
     Sex (male vs. female)     2                    55.2                      0.315               Random                  1.08(0.96, 1.23)   0.193
     Tumor size                2                    0                         0.347               Fixed                   1.01(1.00, 1.02)   0.004
     PSM                       2                    0                         0.860               Fixed                   1.15(1.07, 1.23)   \<0.001

Subgroup Analysis
-----------------

Because the number of studies that evaluated RFS and OM was relatively small, we only conducted subgroup analysis for recurrence. The results of this subgroup analysis again suggested that PSM, bigger tumor size, higher Fuhrman grade and pathological stage were prognostic factors for RCC, despite certain heterogeneity among some groups ([Table 4](#T4){ref-type="table"}). Notably, heterogeneity for recurrence was significantly decreased in some models, such as geographical region in Asia, number of patients ≥800 cases, and year of publication before 2016.

###### 

Summary and subgroup analysis for the prognostic factors in recurrence risk.

  **Analysis specification**                     **No. of studies**   **Study heterogeneity**   **Effects model**   **Pooled HR(95% CI)**   ***P*-value**      
  ---------------------------------------------- -------------------- ------------------------- ------------------- ----------------------- ------------------ ---------
  **Age**                                                                                                                                                      
  Overall                                        8                    34.8                      0.150               Fixed                   1.00(1.00, 1.01)   0.257
  **Surgical approach (laparoscope vs. open)**                                                                                                                 
  Overall                                        4                    0                         0.658               Fixed                   0.80(0.59, 1.07)   0.129
  **PSM**                                                                                                                                                      
  Overall                                        6                    19.1                      0.289               Fixed                   1.47(1.24, 1.73)   \<0.001
  **Sex (Male vs. Female)**                                                                                                                                    
  Overall                                        8                    49.5                      0.054               Random                  1.04(0.89, 1.21)   0.605
  **Geographical region**                                                                                                                                      
     Asia                                        2                    59.1                      0.118               Random                  0.87(0.57, 1.33)   0.514
     Non-Asian                                   6                    20.2                      0.281               Fixed                   1.11(0.97, 1.26)   0.128
  **Year of publication**                                                                                                                                      
     ≥2016                                       5                    67.7                      0.015               Random                  0.98(0.80, 1.22)   0.887
      \<2016                                     3                    0                         0                   Fixed                   1.19(0.94, 1.50)   0.151
  **No. of patients**                                                                                                                                          
     ≥800                                        4                    46.5                      0.133               Random                  1.07(0.89, 1.28)   0.461
      \<800                                      4                    57.8                      0.068               Random                  1.02(0.77, 1.36)   0.886
  **Median follow-Up**                                                                                                                                         
     ≥40 months                                  3                    0                         0.953               Fixed                   1.10(0.86, 1.41)   0.443
      \<40 months                                5                    70.7                      0.009               Random                  1.02(0.82, 1.27)   0.858
  **Fuhrman Grade**                                                                                                                                            
  Overall                                        8                    78                        \<0.001             Random                  1.58(1.10, 2.28)   0.013
  **Geographical region**                                                                                                                                      
     Asia                                        2                    28                        0.239               Fixed                   1.15(0.74, 1.79)   0.541
     non-Asian                                   6                    81.4                      \<0.001             Random                  1.73(1.07, 2.80)   0.025
  **Year of publication**                                                                                                                                      
     ≥2016                                       5                    76.7                      0.002               Random                  1.84(1.16, 2.91)   0.1
      \<2016                                     3                    81.9                      0.004               Random                  1.26(0.63, 2.52)   0.523
  **No. of patients**                                                                                                                                          
     ≥800                                        3                    0                         0.689               Fixed                   1.98(1.45, 2.71)   \<0.001
      \<800                                      5                    81.5                      \<0.001             Random                  1.42(0.88, 2.29)   0.155
  **Median follow-Up**                                                                                                                                         
     ≥40 months                                  2                    0                         0.692               Fixed                   2.12(1.41, 3.19)   \<0.001
      \<40 months                                6                    80.1                      \<0.001             Random                  1.48(0.97, 2.24)   0.067
  **Pathological stage**                                                                                                                                       
  Overall                                        6                    61.9                      0.022               Random                  1.72(1.40, 2.12)   \<0.001
  **Geographical region**                                                                                                                                      
     Asia                                        1                                                                                                             
     Non-Asian                                   5                    44.7                      0.124               Random                  1.60(1.32, 1.93)   \<0.001
  **Year of publication**                                                                                                                                      
     ≥2016                                       4                    69.4                      0.020               Random                  1.69(1.31, 2.19)   \<0.001
      \<2016                                     2                    65.4                      0.089               Random                  1.79(1.10, 2.90)   0.019
  **No. of patients**                                                                                                                                          
     ≥800                                        4                    2.5                       0.380               Fixed                   1.49(1.29, 1.72)   \<0.001
      \<800                                      2                    0                         0.845               Fixed                   2.33(1.83, 2.97)   \<0.001
  **Median follow-Up**                                                                                                                                         
     ≥40 months                                  2                    65.4                      0.089               Random                  1.79(1.10, 2.90)   0.019
      \<40 months                                4                    69.4                      0.020               Random                  1.69(1.31, 2.19)   \<0.001
  **Tumor size**                                                                                                                                               
  Overall                                        7                    81.3                      \<0.001             Random                  1.09(1.03, 1.16)   0.003
  **Geographical region**                                                                                                                                      
     Asia                                        1                                                                                                             
     Non-Asian                                   6                    83.9                      \<0.001             Random                  1.10(1.03, 1.16)   0.002
  **Year of publication**                                                                                                                                      
     ≥2016                                       4                    89.7                      \<0.001             Random                  1.10(1.02, 1.18)   0.015
      \<2016                                     3                    26.0                      0.259               Fixed                   1.10(0.92, 1.31)   0.290
  **No. of patients**                                                                                                                                          
     ≥800                                        4                    38.3                      0.182               Fixed                   1.11(1.07, 1.15)   \<0.001
      \<800                                      3                    40.5                      0.186               Fixed                   1.05(0.84, 1.31)   0.677
  **Median follow-Up**                                                                                                                                         
     ≥40 months                                  4                    49.8                      0.113               Fixed                   1.17(0.98, 1.40)   0.091
      \<40 months                                3                    92.1                      \<0.001             Random                  1.08(1.00, 1.16)   0.045

Sensitivity Analysis and Publication Bias
-----------------------------------------

Sensitivity analysis was performed to examine the stability of the current meta-analysis. As shown in [Supplementary Figure S3](#SM3){ref-type="supplementary-material"}, the overall HRs for recurrence were found to be stable and not altered by removal of any single study. Funnel plots and Begg\'s test were used to assess the publication bias in this meta-analysis. Funnel plots for clinicopathological risk factors and recurrence are shown in [Figure 4](#F4){ref-type="fig"}. Using Begg\'s test, no obvious publication bias was found regarding PSM (*p* = 0.807, [Figure 4A](#F4){ref-type="fig"}), higher pathological stage (*p* = 0.483, [Figure 4B](#F4){ref-type="fig"}), large tumor size (*p* = 0.543, [Figure 4C](#F4){ref-type="fig"}), age (*p* = 0.524, [Figure 4D](#F4){ref-type="fig"}), sex (*p* = 0.728, [Figure 4E](#F4){ref-type="fig"}) and surgical approach (*p* = 0.781, [Figure 4F](#F4){ref-type="fig"}). However, a slight publication bias existed in higher Fuhrman grade (*p* = 0.043). Because the number of included studies was limited, the publication bias for RFS and OM were not assessed.

![Funnel plots of publication bias on the correlation between clinicopathological features and recurrence risk in this meta-analysis: **(A)** positive surgical margin; **(B)** higher pathological stage; **(C)** large tumor size; **(D)** age; **(E)** sex; **(F)** surgical approach.](fonc-10-00286-g0004){#F4}

Discussion {#s4}
==========

RCC is one of the most common cancers, with a major worldwide clinical and public health burden. Improved diagnostics have resulted in the increasing discovery of low stage renal tumors. Although the application of standardized NSS treatment has significantly improved the prognosis of early-stage RCC ([@B31]), tumor recurrence and metastasis is still a serious challenge for doctors and patients. RCC have different clinical and biological characteristics, with an extremely heterogeneous oncological outcome ([@B32]). Therefore, it is necessary to find prognostic predictors to distinguish high-risk patients and improve the overall clinical outcome in RCC.

Several stratification nomograms have been developed to predict the progression and prognosis after NSS in the postoperative setting. Clinicopathological features that are associated with survival outcome have been intensively studied in the past few years. The Kattan nomogram ([@B33]), which contain both clinical and pathological parameters, was the first reported classification system to predict the probability of recurrence in RCC patients. Similarly, the University of California, Los Angeles, Integrated Staging System (UISS) ([@B34]) and TNM stage, tumor size, Fuhrman grade, and tumor necrosis (SSIGN) score ([@B35]) developed from the Mayo Clinic were conducted to predicting the oncological outcome.

However, most studies investigating the prognosis predictors for RCC following NSS are restricted by single-center design, small sample size, or ethnic differences. For example, the Kattan nomogram has low predictive accuracy in French ([@B36]) and Japanese patients ([@B37]). Therefore, the precision of the models may be unsatisfactory, and the proposed nomograms still need to be externally validated before clinical application. Moreover, some researchers have reported that other clinicopathological factors such as sex, age, and race may also influence the RCC patients\' outcomes ([@B38], [@B39]). Neglecting these prognostic parameters may reduce the accuracy of survival predictions. Hence, we aimed to evaluate the significant clinicopathological variables of oncologic outcomes after NSS from a meta-analysis based on all the available data.

To the best of our knowledge, the present meta-analysis is the first comprehensive study to analyze the prognostic value of clinicopathological parameters in RCC patients after NSS. The pooled results indicated that large tumor size, high Fuhrman grade, higher pathological stage, and PSM at surgery were unfavorable predictors for both recurrence and RFS. Similarly, there was a significant correlation of PSM and large tumor size with worse OM in RCC patients. Generally, in the subgroup analysis for recurrence, these adverse features were still an important prognostic marker in RCC patients, regardless of race, publication year, sample size and follow-up duration. Since these clinicopathologic factors are easily obtained, they can be used to guide patient counseling and risk stratification after NSS.

Several limitations in this meta-analysis should be acknowledged. First, all included studies were retrospectively performed, and data extracted from those studies may have led to inherent bias. Although we extract the results from multivariate models, there still confounding factors can\'t be controlled. Second, significant heterogeneity was found among studies. However, subgroup analyses showed that the heterogeneity diminished in some groups. Moreover, the stability of our results was confirmed by sensitivity analysis. Third, only published articles were included, and they were all written in English. Therefore, potential selection bias may existed in our study. Fourth, the number of included studies of RFS and OM were smaller, and relevant data could not be obtained for further analysis. Additionally, publication bias was detected in higher Fuhrman grade for recurrence. It is well known that papers with positive results are more likely to be published.

Conclusion {#s5}
==========

The present study demonstrated that PSM, large tumor size, higher pathological stage and Fuhrman grade were closely associated with poorer prognosis in patients following NSS. However, age, sex and surgical approach were not associated with recurrence, RFS and OM. The findings in our study may help clinicians to identify high-risk patients and formulate treatment decisions. Patients with those with risk factors should be subjected to closer surveillance. Due to the limitations in this meta-analysis, further well-designed studies are required to clarify our results.
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RCC

:   renal cell cancer

NSS

:   nephron-sparing surgery

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

NOS

:   Newcastle Ottawa scale

HRs

:   Hazard ratios

CIs

:   corresponding 95% confidence intervals

RFS

:   recurrence-free survival

OM

:   overall mortality

PSM

:   positive surgical margin

PN

:   partial nephrectomy

SE

:   simple enucleation.
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